Pathomics biomarkers for stratification of clear cell kidney cancers

用于透明细胞肾癌分层的病理组学生物标志物

基本信息

  • 批准号:
    10578582
  • 负责人:
  • 金额:
    $ 21.57万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-02-06 至 2025-01-31
  • 项目状态:
    未结题

项目摘要

Project Summary Pathologic attributes of cancers, such as histology and tumor growth patterns are not quantitatively assessed to date. In every cancer type these parameters effect patient outcomes and are included in risk models of tumor recurrence and overall survival. Algorithms using machine learning and convolutional neural networks allow us to quantify pathology and develop Pathomics biomarkers. Here, we propose to obtain pathomics biomarkers of cancer recurrence/progression that enumerate histology growth patterns (HGPs) in clear cell renal cell cancer (ccRCC). ccRCC is the most common subtype of kidney cancer. In its localized stage, it is treated by nephrectomy. However, about 30% of patients experience disease progression after surgery and may benefit from adjuvant treatment. Deciding whether or not treatment is warranted requires identifying patients who are at a high risk of recurrence. Here, we hypothesize that quantitative biomarkers will improve the risk assessment of patients with ccRCC and propose to develop computer-generated features of tumor growth patterns. We previously defined 13 HGPs and demonstrated their ability to predict overall survival in patients treated for ccRCC. Distinctive features for each HGP will be generated and validated using frameworks of convolutional neural networks that produce probabilities of expression across cancer regions. Further, the distribution of probabilities will be used to obtain biomarkers of expression of each HGP. Using parametric and non-parametric models, HGP-biomarkers will be examined for their association with tumor stage and local mechanisms of ccRCC progression, such as formation of tumor thrombi, regional lymph node metastases or invasion into perinephric adipose tissues. The performance of each algorithm in the project will be evaluated. Altogether, biomarkers developed in this project will provide a starting point to select patients with ccRCC for adjuvant treatment after surgery.
项目摘要 癌症的病理学属性,如组织学和肿瘤生长模式没有定量评估 迄今在每一种癌症类型中,这些参数都会影响患者的预后,并被纳入风险模型, 肿瘤复发和总生存率。使用机器学习和卷积神经网络的算法 使我们能够量化病理学并开发病理学生物标志物。在这里,我们建议获得病理组学 列举透明细胞中组织学生长模式(HGP)的癌症复发/进展生物标志物 肾细胞癌(ccRCC)。ccRCC是肾癌最常见的亚型。在其本地化阶段, 通过肾切除术治疗。然而,约30%的患者在手术后经历疾病进展, 可以从辅助治疗中获益。决定是否需要治疗需要确定 复发风险高的患者。在这里,我们假设定量生物标志物将改善 ccRCC患者风险评估,并建议开发计算机生成的肿瘤特征 增长模式。我们以前定义了13个HGP,并证明了它们预测总生存率的能力。 接受ccRCC治疗的患者每个HGP的独特特征将使用 卷积神经网络的框架,产生跨癌症区域的表达概率。 此外,概率分布将用于获得每种HGP表达的生物标志物。使用 在参数和非参数模型中,将检查HGP-生物标志物与肿瘤的相关性 ccRCC进展的分期和局部机制,例如肿瘤血栓的形成、局部淋巴结转移、局部淋巴结转移和局部淋巴结转移, 转移或侵入肾周脂肪组织。项目中每个算法的性能将 被评价。总而言之,本项目开发的生物标志物将为选择患者提供一个起点 ccRCC用于术后辅助治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BEATRICE S KNUDSEN其他文献

BEATRICE S KNUDSEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BEATRICE S KNUDSEN', 18)}}的其他基金

In vivo effects of sulforaphane supplementation on normal human prostate
补充萝卜硫素对正常人前列腺的体内影响
  • 批准号:
    8095726
  • 财政年份:
    2009
  • 资助金额:
    $ 21.57万
  • 项目类别:
In vivo effects of sulforaphane supplementation on normal human prostate
补充萝卜硫素对正常人前列腺的体内影响
  • 批准号:
    7579160
  • 财政年份:
    2009
  • 资助金额:
    $ 21.57万
  • 项目类别:
Clinical Specimen Management and Characterization Core
临床样本管理和表征核心
  • 批准号:
    7727537
  • 财政年份:
    2009
  • 资助金额:
    $ 21.57万
  • 项目类别:
In vivo effects of sulforaphane supplementation on normal human prostate
补充萝卜硫素对正常人前列腺的体内影响
  • 批准号:
    8295990
  • 财政年份:
    2009
  • 资助金额:
    $ 21.57万
  • 项目类别:
In vivo effects of sulforaphane supplementation on normal human prostate
补充萝卜硫素对正常人前列腺的体内影响
  • 批准号:
    8469006
  • 财政年份:
    2009
  • 资助金额:
    $ 21.57万
  • 项目类别:
In vivo effects of sulforaphane supplementation on normal human prostate
补充萝卜硫素对正常人前列腺的体内影响
  • 批准号:
    8069167
  • 财政年份:
    2009
  • 资助金额:
    $ 21.57万
  • 项目类别:
In vivo effects of sulforaphane supplementation on normal human prostate
补充萝卜硫素对正常人前列腺的体内影响
  • 批准号:
    7898954
  • 财政年份:
    2009
  • 资助金额:
    $ 21.57万
  • 项目类别:
Tissue Lysates for Studies of Protein Phosphorylation
用于蛋白质磷酸化研究的组织裂解物
  • 批准号:
    7503182
  • 财政年份:
    2008
  • 资助金额:
    $ 21.57万
  • 项目类别:
Tissue Lysates for Studies of Protein Phosphorylation
用于蛋白质磷酸化研究的组织裂解物
  • 批准号:
    7684191
  • 财政年份:
    2008
  • 资助金额:
    $ 21.57万
  • 项目类别:
Clinical Specimen Management and Characterization Core
临床样本管理和表征核心
  • 批准号:
    8380131
  • 财政年份:
  • 资助金额:
    $ 21.57万
  • 项目类别:

相似海外基金

Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 21.57万
  • 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
  • 批准号:
    494901
  • 财政年份:
    2023
  • 资助金额:
    $ 21.57万
  • 项目类别:
    Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
  • 批准号:
    10714537
  • 财政年份:
    2023
  • 资助金额:
    $ 21.57万
  • 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
  • 批准号:
    10588103
  • 财政年份:
    2023
  • 资助金额:
    $ 21.57万
  • 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
  • 批准号:
    22K09407
  • 财政年份:
    2022
  • 资助金额:
    $ 21.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
  • 批准号:
    21KK0287
  • 财政年份:
    2022
  • 资助金额:
    $ 21.57万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
  • 批准号:
    10357120
  • 财政年份:
    2022
  • 资助金额:
    $ 21.57万
  • 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
  • 批准号:
    21K08700
  • 财政年份:
    2021
  • 资助金额:
    $ 21.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
  • 批准号:
    437315
  • 财政年份:
    2020
  • 资助金额:
    $ 21.57万
  • 项目类别:
    Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
  • 批准号:
    435603
  • 财政年份:
    2020
  • 资助金额:
    $ 21.57万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了